Subscribe to the MTSL

The Medical Technology Stock Letter (“MTSL“) is published 24 times per year, sent electronically only*. In addition to our redesigned and enhanced website, BioInvest.com, MTSL now provides more timely updates, whitepapers and breaking news than ever before. We offer unique perspectives on medical trends, portfolio companies and focus on diversification and risk management strategies to help investors profit from today’s market volatility. Our philosophy of buying carefully selected biotech stocks at attractive prices and holding them for the long-term hasn’t changed. What has changed is our ability to make MTSL a more valuable tool for today’s discerning investor.


INDIVIDUAL SUBSCRIPTION

For the Retail or Individual Investor**

One Year Subscription

1 Year (24 issues) digital only: $399

Two Year Subscription

2 Year (48 issues) digital only: $678
(15% savings off annual rate)

Three Year Subscription

3 Year (72 issues) digital only: $898
(25% savings off annual rate)

GROUP SUBSCRIPTION

For the Corporate or Institutional Investor**

One Year Subscription

1 Year (24 issues) digital only: $1,899

Two Year Subscription

2 Year (48 issues) digital only: $3,228
(15% savings off annual rate)

Three Year Subscription

3 Year (72 issues) digital only: $4,272
(25% savings off annual rate)


**As of August 2022, we no longer offer print subscriptions to new subscribers. Subscribers can download a PDF copy of the latest issue via a button at the bottom of each issue).

**You may cancel within 48 hours of your subscription date for a full refund. The contents are based on information from sources believed to be reliable, but accuracy and completeness cannot be guaranteed. Nothing herein should be construed as an offer to buy or sell any security. The publisher and its associates, directors or employees may have positions in, and may from time to time make purchases or sales of, securities mentioned herein. We cannot guarantee and you should not assume that future recommendations will equal the performance of past recommendations or be profitable.